Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Gli3 silencing enhances cyclopamine suppressive effects on ovarian cancer
1Department of Gynecology, First Affiliated Hospital of Liaoning Medical College, Jinzhou, People's Republic of China.
Abstract:
Ovarian cancer is a leading gynecological malignancy associated with high mortality. Hedgehog signaling has been found to be important for cell proliferation and tumor growth for multiple cancers, including ovarian cancer. The present study showed that the drug cyclopamine, which blocks the hedgehog signaling pathway, could reduce cancer cell growth and proliferation and induce cell apoptosis. In addition, the silencing of the glioma-associated oncogene (Gli)3, a downstream component of the hedgehog signaling pathway, could further enhance the antitumor effects of cyclopamine. Our results suggest that Gli3 may act as resistance to cyclopamine's effect on tumor growth. The combined treatment of cyclopamine application and Gli3 silencing therapy, therefore, may provide novel directions for clinical management of ovarian cancer.
Insights
Cyclopamine inhibits ovarian cancer growth by blocking hedgehog signaling. Silencing Gli3 enhances this effect, suggesting a combined therapy approach for ovarian cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer is a deadly gynecological malignancy.
- Hedgehog signaling pathway is implicated in cancer cell proliferation and tumor growth.
- Targeting this pathway presents a potential therapeutic strategy.
Purpose of the Study:
- To investigate the effect of cyclopamine, a hedgehog signaling inhibitor, on ovarian cancer.
- To evaluate the role of glioma-associated oncogene (Gli)3 in mediating resistance to cyclopamine.
- To explore the potential of combined cyclopamine and Gli3 silencing therapy for ovarian cancer.
Main Methods:
- Utilized cyclopamine to inhibit the hedgehog signaling pathway in ovarian cancer models.
- Employed Gli3 gene silencing techniques.
- Assessed the impact of these interventions on cancer cell growth, proliferation, and apoptosis.
Main Results:
- Cyclopamine treatment demonstrated significant reduction in ovarian cancer cell growth and proliferation.
- Cyclopamine induced apoptosis in cancer cells.
- Silencing Gli3 potentiated the antitumor effects of cyclopamine, suggesting Gli3 confers resistance.
- Gli3 appears to be a key mediator of resistance to cyclopamine.
Conclusions:
- Gli3 may confer resistance to cyclopamine in ovarian cancer.
- Combined therapy of cyclopamine and Gli3 silencing shows promise for enhancing antitumor effects.
- This combined approach may offer novel therapeutic strategies for managing ovarian cancer.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Related Concept Videos
02:34Inhibition of Cdk Activity
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...